Express News | KPC Pharmaceuticals, Inc.: Completed the acquisition of 51% equity in China Resources Shenghuo.

BreakingsDec 20 16:55

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16 14:21

HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.

HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.

Zhitong FinanceDec 13 07:20

A-share volatility丨KPC Pharmaceuticals, Inc. rises more than 7% to reach a two-month high. Brokerage is bullish on the company's long-term development.

Gelonghui, December 12 | KPC Pharmaceuticals, Inc. (600422.SH) is currently up 7.2%, reaching a new high of 17.23 yuan in two months, with a total market value of 12.9 billion yuan. The latest report from Guosheng Securities indicates that the initial management integration and marketing adjustments of KPC Pharmaceuticals, Inc. have basically been completed. Bullish on the gradual realization of performance, it is expected that 2025 will be the year of performance release. Bullish on the company's long-term development, the first coverage gives a 'Buy' rating. (Gelonghui)

Gelonghui FinanceDec 12 10:23

The A-share Traditional Chinese Medicine Sector collectively surged, with Shaanxi Panlong Pharmaceutical hitting the daily limit.

Gelonghui, December 12 | Panlong Pharmaceutical went up and down, and Xiangxue Pharmaceutical, Kunming Pharmaceutical, Huasen Pharmaceutical, Jingxin Pharmaceutical, Xinguang Pharmaceutical, and Changyao Holdings followed suit. According to the State Administration of Traditional Chinese Medicine, China will promote the construction of traditional Chinese medicine superior specialists in a hierarchical manner to further improve the clinical efficacy of traditional Chinese medicine. By 2029, it will form a traditional Chinese medicine superior specialist network with complete fields of expertise, wide geographical coverage, reasonable structural layout, and obvious characteristics of traditional Chinese medicine. The overall scale of traditional Chinese medicine superior specialties nationwide will reach about 0.01 million.

Gelonghui FinanceDec 12 10:22

Research reports on gold mining丨Guosheng Securities: Initiating a "buy" rating for kpc pharmaceuticals, inc., bullish on the company's long-term development.

Glory Financial December 10th | Guosheng Securities research reports indicate that with the deepening of state-owned enterprise reform, "integration + efficiency improvement" is expected to continue to be realized. kpc pharmaceuticals, inc. (600422.SH) has basically completed the integration of management and marketing adjustments during the early stage of reform, and performance is expected to gradually be realized, with 2025 likely to be the year of performance release. The company has excellent quality: as a leader in Sanqi preparations, it is expected to further develop in the slow disease 'silver economy' field due to its product and first-mover advantages; with a 600-year inheritance of traditional chinese medicine, the product value is expected to gradually be revealed through the business model of china resources sanjiu medical & pharmaceutical. The company is well prepared and the performance elasticity is expected to be gradually released, remaining bullish.

Gelonghui FinanceDec 10 15:48 · Ratings